Bangladesh approves Chinese ‘CoronaVac’ for emergency use

Staff Correspondent

7 June, 2021 12:00 AM printer

Directorate General of Drug Administration (DGDA) of Bangladesh has given emergency use authorization to Chinese Covid-19 vaccine "CoronaVac", manufactured by Beijing-based pharmaceutical company Sinovac Life Sciences Company Limited.

The DGDA gave the approval on June 3, after Incepta Vaccine Ltd applied for its approval for emergency use, sources said. The same vaccine has received emergency use authorization in 22 other countries.

The CoronaVac is the fifth vaccine which has been given the emergency use authorization. However, M/s Incepta Vaccine Limited is the local agent of the vaccine.

On June 1, World Health Organisation (WHO) validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing.

The Sinovac-CoronaVac product is an inactivated vaccine. It’s easy storage requirements make it very manageable and particularly suitable for low-resource settings.

WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of available evidence, WHO recommends the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks.

The vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalization in 100% of the studied population, the WHO report said.

The DGDA sources said the vaccine can be preserved in 2-8 degree Celsius temperature.

Speaking at health bulletin of the DGHS, its spokesperson Dr Md. Robed Amin said the government is discussing the issue of bringing and using the CoronaVac vaccine in the country.